Frontlight ResearchEarly access
Ovarian cancer trials in South Korea
65 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- Where
- Goyang-si, Seoul
- Age
- 18 years and over
- People
- 605 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Goyang-si, Seodaemun-Gu, Seoul, Songpa-gu
- Age
- 18 years and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - Phase 3Taking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Daegu, Seodaemun-Gu, Seoul
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - Phase 1CompletedA Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Where
- Busan, Seoul
- Age
- 18 years and over
- People
- 172 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT04516447 · EU 2025-524868-38-00 - Phase 3Taking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Daegu, Goyang-si, Seoul
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - No phaseTaking peopleA Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Where
- Dalseo-gu, Gwangmyeong, Seongnam, Seoul
- Age
- 35 years to 50 years
- People
- 1,956 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT04251052 - Phase 2Taking peopleInvestigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Where
- Daegu, Gyeonggi-do, Incheon, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 397 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06787612 · EU 2024-517806-27-00 - Phase 3Not yet taking people in South KoreaTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Busan, Daegu, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul, Yangsan
- Age
- 18 years and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - Phase 1Taking peopleA Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Where
- Gwangmyeong, Seoul
- Age
- 19 years and over
- People
- 238 worldwide
- Run by
- NiKang Therapeutics, Inc.
See details and how to joinNCT06586957 - Phase 3Taking peopleA Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Where
- Seoul
- Age
- 18 years and over
- People
- 802 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07776691 · EU 2025-524592-22-00 - Phase 1/2Taking peopleRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Seoul
- Age
- 18 years and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366 - Phase 3Taking peopleEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Where
- Seoul
- Age
- 18 years to 60 years
- People
- 3,960 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05879926 - Phase 1Taking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Goyang-si Gyeonggi-do
- Age
- 18 years and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Taking peopleA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Where
- Gangnam-Gu, Guro-gu, Hwasun-Eup, Jongno-gu, Seodaemun-gu, Seoul, Suwon
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Jongno -Gu, Seoul
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 3Taking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Daegu, Goyang-si, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - Phase 3Taking peopleMo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
- Where
- Seoul
- Age
- 18 years and over
- People
- 720 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07694427 · EU 2025-523365-13-00 - Phase 3Taking peopleA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Seongnam, Seoul
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00 - Phase 2Taking peopleA Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Where
- Goyang-si, Seoul
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825 · EU 2022-502983-19-00 - Phase 3Taking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Daegu, Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - Phase 2/3Active, not recruitingA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Goyang-si, Seongnam, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Not yet taking people in South KoreaTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Goyang-si, Seoul
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00 - Phase 3Taking peopleStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Ansan-si, Changwon-Si, Daegu, Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00